Clinical trial · Interventional
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
NCT04832776CI-TRIAL-00051085unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastasis Colon Cancer | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Cetuximab | Drug | Cetuximab | ALIAS |
| FOLFOXIRI | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- FOLFOXIRI+C225
- interventionNames
- Drug: Cetuximab
- Drug: FOLFOXIRI
- type
- ACTIVE_COMPARATOR
- label
- FOLFOXIRI+BEV
- interventionNames
- Drug: Bevacizumab
- Drug: FOLFOXIRI
Primary outcomes (1)
- measure
- ORR
- timeFrame
- up to 8 weeks
- description
- objective response rate
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * ECOG perfomance 0-1 * pathologically confirmed colorectal carcinoma, with RAS wild type * inital unresectable liver metastases discussed by MDT * prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery. * without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT) * adequate blood, liver and renal function * expected survival longer than 6 months Exclusion Criteria: * with bleeding risk * interestinal obstruction or disease * uncontrolled hypertension and severe heart disease * previous severe thrombotic events * central nervous system metastases * accompanied with other malignant tumor
References
Publications (0)
Data not yet available
No reference posted for this study.